Delcath Systems Inc. (DCTH)
Delcath Systems, Inc. (DCTH) Q1 2026 Earnings Call Transcript
Delcath Systems, Inc. (DCTH) Q1 2026 Earnings Call Transcript
Delcath Systems, Inc. (DCTH) Reports Q1 Loss, Misses Revenue Estimates
Delcath Systems, Inc. (DCTH) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.03 per share a year ago.
Delcath: Fundamentals Intact, Despite Share Price Weakness
Delcath Systems, Inc.'s revenue remains under pressure due to weak patient starts in the third quarter of 2025. The fundamentals of the company remain intact, though, and 2026 should be another year of strong growth. Delcath's profitability will be under pressure due to investments in clinical trials and sales and marketing.
Delcath Systems: Stabilizing Fundamentals Justify A Rating Upgrade
Delcath Systems is upgraded from Hold to Buy as sales stabilize and insider confidence grows. DCTH expects to hit the upper end of 2025 guidance at $85M, signaling operational stabilization after earlier guidance cuts. CHOPIN trial results expand HEPZATO's potential beyond liver therapies, supporting a broader market opportunity.
Delcath: Temporary Headwinds Are No Cause For Concern
Delcath's third quarter was weak due to seasonality and pricing headwinds, but data suggests these are temporary challenges. Delcath continues to expand its treatment sites and sales force, which should lead to strong growth in 2026. Clinical trials to expand the company's addressable market are also now under way, which could provide enormous upside in several years time.
Delcath Systems, Inc. (DCTH) Q3 2025 Earnings Call Transcript
Delcath Systems, Inc. ( DCTH ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Gerard Michel - CEO & Director Sandra Pennell - Chief Financial Officer Vojislav Vukovic - Chief Medical Officer Conference Call Participants Marie Thibault - BTIG, LLC, Research Division John Newman - Canaccord Genuity Corp., Research Division Jake Soucheray Kesav Chandrasekhar Swayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research Division Yale Jen Bill Maughan Presentation Operator ” David Hoffman General Counsel, Corporate Secretary & Chief Compliance Officer ” Gerard Michel CEO & Director ” Sandra Pennell Chief Financial Officer ” Vojislav Vukovic Chief Medical Officer ” Marie Thibault BTIG, LLC, Research Division ” BTIG, LLC, Research Division John Newman Canaccord Genuity Corp., Research Division ” Canaccord Genuity Corp., Research Division Jake Soucheray ” Craig-Hallum Capital Group LLC, Research Division Kesav Chandrasekhar ” Stephens Inc., Research Division Swayampakula Ramakanth H.C.
Delcath Systems, Inc. (DCTH) Q3 Earnings Match Estimates
Delcath Systems, Inc. (DCTH) came out with quarterly earnings of $0.02 per share, in line with the Zacks Consensus Estimate . This compares to a loss of $0.03 per share a year ago.
Delcath: Large Upside With Limited Downside Risk
Delcath offers a liver-directed chemotherapy system, which is currently used to treat metastatic uveal melanoma patients. Delcath is facing pricing pressure and slow hospital onboarding at the moment, adding to concerns about the size of the company's addressable market. Recent clinical data support PHP's efficacy in combination with immunotherapies, potentially broadening adoption and addressing market size concerns.
Delcath Systems, Inc. (DCTH) Q2 2025 Earnings Call Transcript
Delcath Systems, Inc. (NASDAQ:DCTH ) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Gerard J. Michel - CEO & Director Kevin Muir - Corporate Participant Sandra Pennell - Chief Financial Officer Vojislav Vukovic - Chief Medical Officer Conference Call Participants Bill Morgan - Unidentified Company Chase Richard Knickerbocker - Craig-Hallum Capital Group LLC, Research Division I-Eh Jen - Laidlaw & Company (UK) Ltd.
Is the Options Market Predicting a Spike in Delcath Systems Stock?
Investors need to pay close attention to DCTH stock based on the movements in the options market lately.
Delcath Systems: Growing Fast, But Business Model Is Fragile
Delcath's HEPZATO shows rapid sales growth and high pricing, but its efficacy is only moderately better than alternatives and not curative. The addressable market is small, treatment is complex, and future competition from Replimune or Ideaya could threaten long-term prospects and valuation multiples. Financials are solid with no debt, recent profitability, and reasonable stock-based compensation; forward P/S ratio is attractive versus peers.
Delcath Systems, Inc. (DCTH) Is Up 0.62% in One Week: What You Should Know
Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out.
